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Efficacy of External Counterpulsation in Patients with Chronic Stable 
Angina Pectoris on Maximal and Sub-maximal Functional Capacity:  
A Systematic Review and Meta-Analysis 
  
N.F. Tarsidin1, B.B. Tiksnadi1, M.R. Akbar1 
1Department of Cardiology and Vascular Medicine, Dr. Hasan Sadikin General 
Hospital, Universitas Padjadjaran 
  
Background: External counter pulsation (ECP) is a non-invasive therapy that has 
been considered for symptoms relief in patients with chronic debilitating angina. We 
aimed to evaluate ECP efficacy magnitude on maximal and sub-maximal functional 
capacity through systematic review and meta-analysis. 
Methods:  A systematic literature search of studies from MEDLINE database 
between 1990 to May 2021 was performed. Studies were included for meta-analysis if 
they were reported adequate data on maximal and sub-maximal Functional capacity 
test data at baseline and after ECP in chronic stable angina pectoris patients. The ECP 
treatment consisted of 35 outpatient sessions-1 hour/day, 5 days/week, for 7 weeks. 
The efficacy of ECP on maximal functional capacity calculated using standardized 
mean difference (SMD) to address protocol variety used in the test. Nonetheless, the 
efficacy of ECP on sub-maximal functional capacity was assessed using mean 
difference (MD). Publication bias was assessed through visual inspection of the 
funnel plot 
Result: There were 25 studies consisted of 19 studies (n=581) assessed maximal and 
6 studies (n=3027) assessed sub-maximal functional capacity were enrolled in meta-
analysis. ECP therapy has significant effect to improved maximal functional capacity 
(SMD 1.02, 95%CI 0.64 to 1.41, p<0.00001, I2=89%) and improved sub-maximal 
functional capacity by 63 meters (MD 62.82, 95%CI 32.90 to 92.73, p<0.0001, 
I2=83%). There was no evidence of significant publication bias in studies assessed 
maximal functional capacity. 
Conclusion: ECP therapy provides a significant improvement in maximal and sub-
maximal functional capacity. Therefore, these findings broaden ECP therapy efficacy 
magnitude in managing chronic stable angina pectoris patients. 
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Left Ventricular Improvement in Heart Failure with Reduced Ejection Fraction 
After Angiotensin Receptor – Neprilysin Inhibitor Administration: A Meta-
Analysis 
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Background: Heart failure (HF) is an end-stage of all cardiovascular disease. Heart 
failure with reduced ejection fraction (HFrEF) is associated with the progressive 
reduction of left ventricular (LV) function and an increased risk of mortality. A 
previous study showed that Angiotensin Receptor - Neprilysin Inhibitor (ARNI) 
significantly reduced the risk of death compared to enalapril. However, LV function 
improvement after ARNI administration remains less studied. 
Method: We performed a systematic literature search from several electronic 
databases. The inclusion criteria were a Randomized Control Trial (RCT) or 
observational study which reported echocardiography follow up after ARNI 
administration. The primary endpoint was LVEF. Secondary endpoints were LVEDD, 
LVEDV, LVESD, LVESV, and LAVI. All outcomes were reported as mean 
difference (MD) with 95% confidence intervals (CIs). 
Results: A total of 1 RCT and 17 observational study were selected, with 2.953 
patients were pooled in our analysis. After ARNI administration LVEF was 
significantly increase (MD=7.17 [95% CI, 5.53,8.80],p<0.00001). LVEDD was 
decreased (MD=-2.18 [95% CI, -2.50,-1.85],p<0.00001). LVEDV was decreased 
(MD=-16.40 [95% CI, -24.96,-7.84], p=0.0002). LVESD was decreased (MD=-4.33 
[95% CI, -5.58,-3.09], p<0.00001). LVESV was decreased (MD=-21.34 [95% CI, -
34.00,-8.68],p=0.001). LAVI was decreased (MD=-5.12 [95% CI, -9.63,-
0.60],p=0.03). 
Conclusions: ARNI is not only preventing further cardiac remodeling in HFrEF but 
also reverses LV function. ARNI may be useful in cardiac rehabilitation. 
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Figure 1. Forest plot of meta-analysis LVEF improvement between Pre and Post 
ARNI 
 
 
